Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

95P - Promising biomarkers for therapeutic targets and prognosis of triple-negative breast cancer (TNBC)

Date

17 Sep 2020

Session

E-Poster Display

Topics

Targeted Therapy

Tumour Site

Breast Cancer

Presenters

Sujin Yang

Citation

Annals of Oncology (2020) 31 (suppl_4): S274-S302. 10.1016/annonc/annonc266

Authors

S. Yang1, J. Tang2

Author affiliations

  • 1 Department Of General Surgery, Jiangsu Provincial People’s Hospital (The First Affiliated Hospital of Nanjing Medical University), 210029 - Nanjing/CN
  • 2 Department Of General Surgery, Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University, 210029 - Nanjing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 95P

Background

Previous studies have shown that triple-negative breast cancer (TNBC) owned a higher degree of malignancy clinically, and its tumor progression rate was much higher than that of other types of breast cancer. TNBC is more common in young women, with rapid tumor growth, lack of effective treatment and poor prognosis. Therefore, it is urgent to discover new molecular targets for the treatment and prediction of TNBC progression and prognosis.

Methods

We analyzed the differences between 13 TNBC cell lines and 2 normal breast cell lines. Moreover, RNA-sequencing techniquewas used to determine the level of differential expressed mRNAs in tumor samples from TNBC patients (n=55) compared with non-TNBC patients [Her2 positive (n=39), Lumina A (n=29), Lumina B (n=30), Healthy control (n=11)]. Then, we used qRT-PCR to confirm the differential-expressed mRNAs in breast cancer cell lines. Furthermore, we used the survival data of in the TCGA database to predict the effect of theses mRNAs on the prognosis of TNBC patients.

Results

We analyzed the microarray of different cell lines and found that 1709 differentially-expressed mRNAs in TNBC cell lines compared with normal breast cell lines. Moreover, we profiled the mRNAs in the tumor samples from TNBC patients and non-TNBC patients and detected: 1098 differentially-expressed mRNAs in TNBC compared with healthy control, 209 differentially-expressed mRNAs in TNBC compared with Her2 positive, 659 differentially-expressed mRNAs in TNBC compared with Lumina A and 361 differentially-expressed mRNAs in TNBC compared with Lumina B. Comprehensive analysis of the above results, we found 6 mRNAs (NR2F1, TFF3, COL10A1, NTN4, MMP12, SFRP1) dysregulated in TNBC cell lins and tissue. Kaplan-Meier plots showed the lower expression of SFRP1 and the higher expression of COL10A1 was connected to poor prognosis in TNBC patients from TCGA database.

Conclusions

The expression of NR2F1, TFF3, COL10A1, NTN4, MMP12, SFRP1 were found significantly dysregulated in TNBC cells and tumor tissues. Moreover, the expression level of SFRP1 and COL10A1 are related to the prognosis of TNBC patients. Therefore, this study provides a fresh perspective on novel therapeutic targets and potential biomarkers for TNBC patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Sujin Yang.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.